What is the recommended dosing for Keppra (Levetiracetam) XR in patients with epilepsy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Levetiracetam XR (Keppra XR) Dosing for Epilepsy

For adult patients with epilepsy, Levetiracetam XR should be initiated at 1000 mg once daily and can be titrated up to a maximum recommended dose of 3000 mg once daily, with dosage increases of 1000 mg every 2 weeks based on clinical response and tolerability. 1

Adult Dosing (16 years and older)

Partial Onset Seizures

  • Initial dose: 1000 mg once daily
  • Titration: Increase by 1000 mg every 2 weeks as needed
  • Recommended maintenance dose: 1000-3000 mg once daily
  • Maximum dose: 3000 mg once daily

Myoclonic Seizures (12 years and older with juvenile myoclonic epilepsy)

  • Initial dose: 1000 mg once daily
  • Titration: Increase by 1000 mg every 2 weeks
  • Recommended maintenance dose: 3000 mg once daily

Primary Generalized Tonic-Clonic Seizures

  • Initial dose: 1000 mg once daily
  • Titration: Increase by 1000 mg every 2 weeks
  • Recommended maintenance dose: 3000 mg once daily

Pediatric Dosing (4 to <16 years)

For children, the immediate-release formulation is recommended with twice-daily dosing:

  • Initial dose: 20 mg/kg/day divided into two doses (10 mg/kg twice daily)
  • Titration: Increase by 20 mg/kg every 2 weeks
  • Recommended maintenance dose: 60 mg/kg/day divided into two doses (30 mg/kg twice daily)

Administration Considerations

  • Levetiracetam XR can be taken with or without food 1
  • Only whole tablets should be administered (do not break, crush, or chew extended-release tablets)
  • For patients who cannot swallow tablets, the immediate-release formulation should be used

Efficacy and Dose-Response Relationship

Clinical studies have demonstrated a dose-dependent efficacy of Levetiracetam:

  • At 1000 mg/day: Significant reduction in seizure frequency compared to placebo 2
  • At 2000 mg/day: Greater response rate compared to 1000 mg/day in within-patient comparisons 2
  • At 3000 mg/day: Recommended for myoclonic seizures and primary generalized tonic-clonic seizures 1

Special Populations

Renal Impairment

  • Dose adjustment is necessary based on creatinine clearance
  • For patients on dialysis, supplemental doses may be required following dialysis

Elderly

  • Start at lower doses and titrate more slowly due to potential for decreased renal function

Common Adverse Effects

The most frequently reported adverse events with Levetiracetam XR include:

  • Somnolence
  • Irritability
  • Dizziness
  • Nausea
  • Influenza
  • Nasopharyngitis 3

Clinical Pearls

  • Levetiracetam XR allows for once-daily dosing, which may improve medication adherence 3
  • The extended-release formulation provides relatively constant plasma concentrations, which may minimize concentration-related adverse effects 3
  • Levetiracetam has minimal drug-drug interactions and does not affect the serum levels of other antiepileptic medications 4
  • High retention rates (approximately 80-85%) have been observed in clinical studies, indicating good tolerability 5, 6
  • Seizure freedom rates of 5.5-6.3% have been reported at doses of 1000-2000 mg/day 2

Monitoring

  • No routine blood level monitoring is required due to Levetiracetam's wide therapeutic index and linear pharmacokinetics 3
  • Monitor for behavioral changes, particularly irritability and aggression
  • Assess seizure frequency and adverse effects at each follow-up visit

Levetiracetam XR's favorable pharmacokinetic profile, including minimal protein binding (<10%), linear kinetics, and minimal metabolism through pathways independent of the cytochrome P450 system, makes it an excellent option for adjunctive therapy in epilepsy management 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.